InvestorsHub Logo
Followers 58
Posts 10088
Boards Moderated 1
Alias Born 09/21/2016

Re: None

Saturday, 09/02/2017 8:59:17 AM

Saturday, September 02, 2017 8:59:17 AM

Post# of 459910
https://www.fool.com/investing/2017/09/01/3-reasons-gilead-sciences-bought-kite-pharma.aspx?yptr=yahoo

The Kite acquisition gives Gilead a near-term opportunity with axicabtagene ciloleucel (axi-cel), which is essentially an I.V. bag full of the patient's own immune cells that have been reprogrammed to hunt for cancer cells that display the CD19 protein on their surface. The personalized cell-based therapy works incredibly well for patients with non-Hodgkin lymphomas who have relapsed after receiving available treatments; the FDA is expected to announce its  decision about the treatment's approval by the end of November



You do not have to be a scientist to notice comments like this recent one involving a massive investment by Gilead. Stop me if you see a theme developing. Again not very scientific but, when a dear little girl develops Rett after months of apparent "normalcy" and A2-73 possibly "restores" functionality lost to some microxxxx....it's about time we figured this out. I understand it is a lot more complicated and I have highest respect for that knowledge, but this restorative treatment just feels right. Let the body heal itself, what a concept.

With luck, gone are the dark days of poisoning someone or bombarding them with radiation to save them. Those days will soon be right up there with bleeding and leaches cures. Your brain really does not have to bleed in order for you to recover, trust the process. This will not be easy, there are lots of players and many conflicts. Maybe Dr.M. chose Rett to be first b/c he understood that even the meanest of the political/medical naysayers will be speechless if A2-73 works. Brilliant, Pray it all happens soon.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News